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 Abstract 
Introduction: CD10 is a cell membrane-bound endopeptidase which is expressed in normal 
small bowel but not in normal colon. It is aberrantly expressed in a small proportion of 
colorectal cancers (CRC) and this has been associated with liver metastasis and poor 
prognosis. We sought to investigate the mechanism of CD10 activity and its association with 
clinicopathological features. 
Material and methods: CD10 was stably knocked down by lentiviral shRNA transduction in 
the CRC cell lines SW480 and SW620 which are derived from a primary tumour and its 
corresponding metastasis respectively. Expression of epithelial – mesenchymal transition 
(EMT) markers was tested as well as the effect of knockdown on cell viability, migration and 
invasion assays. In addition, immunohistochemical expression of CD10 in primary colorectal 
tumours (N=84) in a tissue microarray was digitally quantified and analysed for associations 
with clinicopathological variables.  
Results: Knockdown of CD10 did not alter cell viability in SW480, but migration and invasion 
levels increased (P<0.001 for each) and this was associated with a cadherin switch. In SW620, 
CD10 knockdown caused a reduction in cell viability after 72 hours (P=0.0018) but it had no 
effect on cell migration and invasion. Expression of epithelial CD10 in primary tumours was 
associated with presence of lymph node invasion (P=0.001) and advanced Duke’s stage 
(P=0.001). 
Conclusions: Our results suggest that the function of CD10 may change during tumour 
evolution. It may inhibit cell motility in early-stage disease whilst promoting cell viability in late-
stage disease. It has a complex role and further studies are needed to elucidate the suitability 
of CD10 as a prognostic marker or therapeutic target. 
Keywords: CD10, NEP, CALLA, colorectal cancer, epithelial-mesenchymal transition, 
metastasis 
Introduction 
CD10 (cluster of differentiation 10, also designated as neprylisin, membrane metallo-
endopeptidase (MME), neutral endopeptidase (NEP) and common acute lymphoblastic 
leukemia antigen (CALLA) is a zinc-dependent metalloendoprotease which degrades peptides 
involved in cancer signalling pathways (Maguer-Satta et al. 2011). CD10 is expressed in a 
variety of cells. It is expressed in bone marrow lymphoid stem cells, pro-B lymphoblasts, and 
mature neutrophils and it is used for classification of leukaemias and malignant lymphomas(Lu 
et al. 2016). It is also seen in the endometrial stroma and, with regards to the epithelium, it is 
found to be expressed in the lumina of renal tubules, hepatic sinusoids and the microvilli of 
the small intestine (Lloyd & Owens 2011; Iwase et al. 2014; Katano et al. 2017). 
In solid tumours, CD10 over-expression has found use as a diagnostic marker to distinguish 
benign from malignant breast phyllodes tumours (Ibrahim 2011; Tariq et al. 2015; Puri et al. 
2016) and it has been associated with a poor prognosis in malignant breast cancer (Jana et 
al. 2014). Similarly, in prostatic cancer cases, CD10 expression was found to correlate with 
elevated pre-operative prostate-specific antigen (PSA), higher Gleason score and advanced 
stage (Fleischmann et al. 2008). 
CD10 is normally absent in healthy colonic mucosa  but it can be aberrantly expressed in both 
the epithelium and stroma of colorectal tumours and an association with advanced disease is 
reported (Ogawa et al. 2002). It is not expressed in adenomas with low grade dysplasia but 
aberrant expression – in both stromal and epithelial compartments – is seen in adenomas with 
high-grade dysplasia and in invasive adenocarcinomas (Ogawa et al. 2002). CD10 expression 
has also been associated with increased tumour invasiveness, accumulation of p53 and large 
tumour size (Ogawa et al. 2002). Moreover, CD10 expression is a significant risk factor for the 
development of liver metastasis (Fujita et al. 2010; Ohji et al. 2007) and elevated CD10 serum 
levels have also been shown to be specific predictors of synchronous and metachronous liver 
metastasis in a cohort of human patients (Sasaki et al. 2014). In a mouse model of metastatic 
colorectal cancer, CD10 causes degradation of the anti-proliferative protein hepatic met-
enkephalin thereby enhancing tumour growth (Kuniyasu et al. 2010).  
CD10 may also play a role in metastasis in CRC. For metastasis, cells need to undergo 
epithelial to mesenchymal transition (EMT). During EMT epithelial cells lose their junctions, 
reorganise their cytoskeleton and undergo a transformational morphological and programming 
change, which consequently enables an invasive phenotype (Lamouille et al. 2014). Invasive 
cells may reach blood vessels, circulate to distant organs and settle at the secondary site. For 
growth at the metastatic site, cells need to undergo the reverse process of mesenchymal to 
epithelial transition (MET) resulting in formation of metastatic deposits.  
We hypothesized that CD10 may have a role in the formation of metastasis through the 
regulation of the EMT and/or MET processes and thereby altering the motility and invasion of 
colorectal cancer cells. To test this hypothesis, a stable CD10 knockdown was performed by 
lentiviral transduction of shRNA in two cell lines obtained from the same patient but derived 
from the primary tumour and its corresponding metastasis. This allowed us to perform 
functional assays to assess the role of CD10 at the different stages of colorectal cancer in 
cells with the same genetic background.  
Material and methods 
Cell culture 
Colorectal Cancer cell lines SW620 (ATCC® CCL-227™) and SW480 (ATCC® CCL-228™) 
were grown in complete high-glucose DMEM (Dulbecco’s Modified Essential Medium; Gibco 
Life Technologies) supplemented with 2mM L-glutamine and 10% fetal bovine serum (Sigma 
Aldrich) and incubated at 37C, 5% CO2 atmosphere in a humidified incubator. 
 
Lentiviral transduction of shRNA targeting CD10 and Luciferase 
The short hairpin RNA (shRNA) for CD10 and LUC (Luciferase) knockdown were selected 
using the online tool ‘siRNA at Whitehead’ (freely available from 
http://sirna.wi.mit.edu/home.php), using the pattern N2[CG]N8[AUT]N8[AUT]N2 and filtering 
off-targets with least three mismatches (Pei & Tuschl 2006). 
shRNA oligo (5’-3’) 
CD10 Sense  CCGGGCTGGTTGAAACGTAATGTTTCTCGAGTTCGACCAACTTTGCATTACATTTTTG 
CD10 Antisense  AATTCAAAAAGCTGGTTGAAACGTAATGTTTCTCGAGTTCGACCAACTTTGCATTACA 
LUC Sense  CCGGGGCGGAAAGTCCAAATTGTTTCTCGAGTTCCGCCTTTCAGGTTTAACATTTTTG 
LUC Antisense  AATTCAAAAAGGCGGAAAGTCCAAATTGTTTCTCGAGTTCCGCCTTTCAGGTTTAACA 
Table 1. shRNA oligonucleotides for CD10 and LUC. 
The shRNA oligos (table 1) were annealed at 95°C for 4 minutes in a PCR thermal cycler and 
slowly cooled down overnight. The annealed oligos were ligated into pLKO.1-TRC (Addgene 
plasmid #10878), transformed in chemocompetent E.coli, isolated by miniprep and double-
digested with restriction enzymes AgeI and EcoRI. Correctly inserted oligos were confirmed 
by restriction enzyme double-digestion with EcoRI and NcoI of the resulting vectors and 
sequencing. Restriction enzymes and chemocompetent E. coli were supplied by New England 
Biolabs. 
Viral particles were packaged in HEK293T cells seeded at a density of 1.5x106/10cm petri 
dishes in a proportion of 24μL Fugene 6 (Promega, E2691) in 136μL serum-reduced OPTI-
MEM (Gibco, Invitrogen) to 2μg pLKO.1 shRNA plasmid: 1500ng psPAX2 packaging plasmid 
(Addgene #12260): 500ng pMD2.G envelope plasmid (Addgene #12259) to 40μL serum-
reduced OPTI-MEM. After transfection, shRNA lentiviruses were concentrated by 
ultracentrifugation at 10,000xg, 4°C, 4h in a 10% sucrose buffer (Jiang et al. 2015). 
For stable transfection, SW480 and SW620 cells were pre-treated with 8μg/mL polybrene 
(Sigma-Aldrich, #H9268) for 10 min and transduced with viral particles containing transfer 
vectors pLKO.1-TRC-shCD10 or pLKO.1-TRC- shLUC (negative control) for at least 48h. 
Transduced cells were selected by treatment with puromycin (Sigma-Aldrich, #P8833) at a 
pre-tested concentration between 5-10μg/mL which caused 100% cell death in untransduced 
cells. Lentiviral particle production and transduction procedures were adapted from the 
available protocol supplied by Addgene (Plasmid 10878. Protocol Version 1.0. December 
2006), previously used in the preparation of lentiviral shRNA libraries (Moffat et al. 2006). 
CD10 knockdown in SW620 is annotated as SW620CD10-, whilst luciferase controls are 
annotated as SW620LUC-. A similar annotation scheme is used for SW480.  
Protein extraction and Western blot 
Cells were washed with ice-cold PBS and incubated on ice for 10min with RIPA buffer with 
protease and phosphatase inhibitor diluted to 1x. The resulting cell lysates were centrifuged 
at 16000g, at 4C for 30 min and the supernatant transferred to a new eppendorf tube. Protein 
quantification of the supernatant was performed with the Pierce BCA Assay Kit (Thermo 
Scientific) according to manufacturer's instructions. 
For Western blotting, 50µg of protein sample mixed with 25%(v/v)NuPAGE® LDS Sample 
buffer(4x) and 10%(v/v)reducing sample buffer (10x) were denatured at 95°C for 5 min, 
incubated in ice for 5 minutes and then loaded into to a pre-cast gel (NuPAGE® 4-12% Bis-
Tris Protein Gels, Invitrogen). Gel electrophoresis was performed for 90 min at 125V. The 
resulting gel was immunoblotted onto a polyvinylidene difluoride (PVDF) membrane 
(Amersham, GE Healthcare Life Sciences) at 25V for 30 min, using the BIO-RAD® Trans-Blot 
Transfer system.  
After confirming transfer by Ponceau Red staining, blocking to prevent non-specific protein 
binding was carried out by incubating the membrane with 5% skimmed milk (Sigma-Aldrich) 
or bovine serum albumin (BSA) (ThermoFisher Scientific) in tris-buffered saline 0.1% Tween-
20 (TBST) for 1 hour with gentle agitation at room temperature. The membrane was incubated 
overnight with primary antibody, at 4°C with gentle agitation and then was washed 3x 5min 
with TBST. It was incubated with the appropriate HRP-conjugated secondary antibody for 1 
hour at room temperature, using the blocking solution as the diluent. Diluents and antibodies 
used are detailed on table A1 (Supplementary data). The membrane was further washed 3x 
5min in TBST and chemiluminescence was developed using the Amersham ECL Western 
Blotting Detection Reagent (GE Healthcare Life Sciences). Immunoblots were scanned and 
analysed by densitometry with the C-DiGit® Blot scanner and Image studio system (LI-COR). 
Ratios of Target protein/ -Tubulin intensity ratio and the relative knockdown (KD vs 
Luciferase control) were calculated (Supplementary figure A1).  
Immunofluorescence staining 
SW620CD10-, SW620LUC-, SW480CD10- and SW480LUC- were seeded at a density of 2.0 x104 cells 
per well of a chamber slide and incubated overnight at 37°C in a 5%CO2 incubator. Cells were 
washed in PBS (phosphate buffered saline), fixed by incubation in 4% paraformaldehyde, 
permeabilized by 0.1% triton-X 100 PBS and blocked for 1h with 1%BSA, 0.1% tween 20, 
22.52mg/mL glycine PBS. CD10 rabbit anti-human antibody diluted 1:100 (Abcam, EPR5904-
110 ab208778) and alpha-tubulin mouse anti-human diluted 1:200 (Abcam, DM1A ab7291), 
were incubated overnight at 4°C, after 3x5 min washes in 0.1%Tween 20 in PBS (PBST) 
secondary antibodies Alexa-Fluor 568 goat anti-rabbit secondary antibody and Alexa-Fluor 
488 goat anti-mouse secondary antibody (Invitrogen) were incubated for 1h, followed by 
another 3x 5min washes in PBST. Nuclei were stained by incubation with DAPI (Sigma 
Aldrich) diluted 1:5000, for 15min and slides were mounted with fluoroshield anti-fade 
mountant (Sigma Aldrich). The slides were imaged on a Leica SP2 confocal microscope using 
the 63x objective with immersion oil. 
Cell viability assays and cell cycle analysis 
For cell viability, 1×104 cells of each condition of interest (i.e. SW620CD10-, SW620LUC-, 
SW480CD10- and SW480LUC-) were seeded in each well of a 96 well plate. For each condition, 
12 replicate wells were seeded and an individual plate was set up for each of 4 time points. 
Cells were cultured in a volume of 100μl and incubated at 37ºC, 5% CO2. Cell viability was 
quantified using a resazurin-based assay with PrestoBlue® Cell Viability Reagent (Invitrogen) 
diluted to 10% in cell culture media. To allow correction to the background fluorescence 6 
control wells containing only the assay reagent were included. The plate was incubated at 
37ºC for 1 hour and relative fluorescence was read at 544nm excitation and 612nm emission 
(FlexStation 384, Molecular Devices). Readings were taken at 0, 24, 48 and 72 hours. To 
compare between different cell lines, RFU values were normalised to the first performed 
reading and results expressed as relative cell viability. 
For the cell cycle analysis, 1x105 cells of each transduced type were seeded into each well of 
a 24-well plate in quintuplicates and incubated overnight at 37ºC, 5% CO2. A single cell 
suspension was obtained by trypsinization, washed in PBS and fixed in 70% cold ethanol for 
30 min at 4°C, washed twice in PBS and treated with 50µL of a 100µg/mL stock solution of 
RNAse (Qiagen). Cells were again re-suspended in 300 µL of PBS and nucleic acids stained 
with 10 µL of propidium iodide stock solution at 1mg/mL (Sigma Aldrich). Acquisition was 
performed on the FL3 channel of a Cytomics FC500 (Beckman Coulter) and cell cycle 
parameters analysed on Weasel v 3.0.  
Migration and invasion assays 
Cell migration and invasion assays were performed using 24-well polycarbonate transwell 
membrane inserts (pore size 8μm; Corning®). For the migration assay, 1×105 cells were 
added to the uncoated transwell membrane inserts in 100μL. For the invasion assay, matrigel 
Matrix (Corning® Matrigel® Matrix) diluted in cold PBS (100μL, 300μg/mL) was incubated for 
2 hours at 37ºC to coat the transwell insert. 
For both the migration and invasion assays, cells were seeded in the top chamber in serum-
free DMEM. DMEM with 10% FBS, 2mM L-Glutamine (650μl) was used as a chemoattractant 
in the receiver well. Quintuplicates of the CD10 knockdown and luciferase control were used 
for both assays and for each condition wells were established without chemoattractant as a 
negative control for the motility inducing effects of the serum.  
After 24 hours incubation, non-invading cells were removed from the upper chamber. The 
bottom of the transwells was trypsinized (650μl trypsin) and trypsinized cells were transferred 
to the previous receiver well and stained with 4µM of live-cell stain calcein AM (ThermoFisher 
Scientific) by incubation for 30min at 37ºC under 5% CO2. 
The receiver wells were imaged using an inverted fluorescent microscope at 10x magnification 
on the FITC channel. To calculate the total number of cells per insert, the mean total number 
of cells per random microscope field of view (0.055m2) was counted in 4 fields of view and 
used to estimate the total number of migrated cells present at the bottom of the well (1.9cm2). 
Quintuplicates were compared for CD10 knockdown and luciferase control cells. Control wells 
included no chemoattractant and also no coating for the invasion assay. 
Immunohistochemistry (IHC) technique on tissue microarrays (TMAs) 
Immunohistochemical (IHC) staining was performed on a tissue microarray slides (TMA) made 
from a series of 84 primary colorectal cancers. This series was created specifically for the 
purpose of evaluating biomarker expression in colorectal tumours and there was an unbiased 
selection of consecutive cases collected in Nottingham Sciences Biobank at the Queens 
Medical Centre, Nottingham, UK. Local ethical approval was granted prior to the construction 
of the TMAs, destined to IHC studies. Formalin-fixed paraffin embedded tissue blocks were 
retrieved from the archives and a TMA established as previously described (Albasri et al. 
2014).  
The TMA set included cores collected from luminal, mid-tumour, advancing edge areas of 
each tumour and, where possible, adjacent normal areas. Information on clinicopathological 
parameters tumour grade, primary tumour invasion, vascular invasion, Duke’s stage, resection 
margin, KRAS mutation status and presence of lymph node metastasis was retrieved from 
histopathology reports preserving the patient anonymity. A summary of the clinicopathological 
characteristics in the tumour series studied is shown on table B1. 
Tissue sections of 4µm thickness were prepared onto poly-L-lysine coated slides 
(ThermoFisher Scientific, Menz glaser), deparaffinised in xylene, rehydrated by immersion in 
graded methanol and equilibrated in running tap water for 5 min. 
Heat-induced antigen retrieval was performed by immersing the tissue sections in 1mM EDTA 
buffer pH 9.0 microwaved for 20 min at 95C. After cooling, slides were mounted in Shandon 
coverplates and sequenza racks (ThermoFisher Scientific) for the remainder IHC incubation 
steps. For the rest of the procedure, underlined reagents are components of the Novolink 
Polymer kit (Leica Microsystems) and were used according to manufacturer’s instructions. 
Endogenous peroxidases were blocked using peroxidase block for 5 min. Non-specific 
antibody binding was blocked by incubation with protein block for 5 min and washed in TBS 
(tris-buffered saline). 
Each slide was incubated overnight at 4°C with rabbit anti-Human CD10 primary antibody 
(cloneEPR5904-110, ab208778, Abcam) at a 1:2000 dilution. An isotype control anti-rabbit 
IgG was used at the same concentration as the primary antibody. After 3x5min washes with 
TBS, Post-primary reagent was incubated for 30 min at room temperature, followed by 3x 
5min TBST washes and incubation with Novolink Polymer for 30min. Diaminobenzidine (DAB) 
working solution was applied for 5 min, followed by a final wash in TBS. 
Slides were then counterstained using haematoxylin and excessive stain removed by washes 
in tap water. After dehydration in methanol and xylene sections were mounted using mounting 
medium (DPX).Finally, slides were digitalised using a nanozoomer scanner (Hammamatsu).  
Digital image analysis was performed on the software Strataquest v.6.0 (Tissue Gnostics). 
After colour separation and classifier-based tumour epithelium-stroma segmentation, ratios 
(%) were calculated for the CD10 positive epithelial area in the total tumour epithelium and 
CD10 positive stromal area within the total tumour stroma of each individual core.  
Misidentified epithelial and stromal areas were manually corrected if needed after individual 
verification of the segmentation results. The values of CD10 positive epithelium ratios for 
luminal, mid-tumour and advancing edge cores were added to calculate the total CD10 
epithelium score. 
Statistical analysis 
GraphPad Prism 7.01 (CA, USA) was used for statistical analysis of in vitro assays. Two-way 
analysis of variance (ANOVA) was performed to analyse proliferation assays and cell cycle 
analysis. Unpaired Mann-Whitney T-test (non-parametric test) was performed to compare 
means in protein expression, migration and invasion assay results. The statistical software 
SPSS (Statistical Package for the Social Sciences, IBM, OH, USA) version 22.0 was used for 
IHC statistical analysis of associations with clinicopathological variables by Pearson Chi-
square test. The normality test Kolmogorov–Smirnov was firstly applied to confirm the 
population followed a non-Gaussian distribution. Cut off values were determined by the 
median value of the total epithelial or stromal CD10 score. In all statistical comparisons, 
p<0.05 was accepted as denoting significance difference. 
 
Results 
 
Confirmation of CD10 knockdown by Western Blot and Immunofluorescence 
After transduction with lentiviruses expressing shCD10 or shLUC oligos, the protein level was 
measured by Western Blot. CD10 protein expression was visibly decreased for both 
transduced shC10 cell lines (SW480CD10- and SW620CD10-, Figure 1). These changes were also 
visible by immunofluorescence staining of CD10, where the fusiform morphology acquired by 
SW480CD10- could also be observed (Figure 2). 
Effect of CD10 knockdown on cell viability 
Cell viability was assessed at over a time course of 72 hours. In SW480CD10- cell viability was 
not altered as growth curves of the cells were identical to SW480Luc (Figure 3A). In contrast, 
in SW620CD10- a delayed inhibition of cell growth which only became apparent after 72 hours 
(Figure 3B and B1). A cell cycle analysis confirmed a small but significant decrease in the 
G2/M  phase post CD10 knockdown in SW620CD10-  and SW480CD10- (P=0.0143 and P=0.0059 
respectively, Figure 2C). 
Effect of CD10 knockdown on cell migration and invasion 
Since no difference was observed in the effect of CD10 knockdown on the proliferative activity 
at 24h, there was no need to block cell replication before performing migration and invasion 
assays (which are conducted in 24h). In SW480CD10- cells, the knockdown of CD10 resulted in 
an increase in cell motility. A statistically significant increase in cell numbers was observed in 
both the transwell migration and invasion assays when compared to the control cell line 
(P<0.001) (Figure 3, C and D). In contrast, in SW620CD10-, no significant differences were 
observed in either transwell migration or invasion assays between CD10 knockdown and 
luciferase control (Figure 3, A and B).  
Identification of CD10-associated EMT Markers 
Expression of a variety of biomarkers related to the EMT process was assessed by Western 
blot. E-Cadherin and N-Cadherin are cell adhesion molecules and ordinarily, in the non-motile 
state, E-cadherin levels are high whilst N-Cadherin levels are low. When cells become motile, 
the levels are reversed with high N-Cadherin and low E-cadherin (known as the “cadherin 
switch” (Maeda et al. 2005). CD10 knockdown in SW480 resulted in a cadherin switch 
resulting in reduced E-Cadherin expression and increased N-Cadherin expression (Figure 1, 
Supplementary Figure 1) thus complementing the observed changes in cell motility. 
Evaluation of other EMT markers showed that, despite the cadherin switch and increased 
motility, Snail and Twist were reduced and Vimentin remained unchanged. However, these 
changes were not seen with CD10 knockdown in SW620 – there was no cadherin switch and 
the expression of Snail, Twist and vimentin was unchanged. CD10 Knockdown was 
associated with slight increase on N-Cadherin and E-Cadherin expression (Figure 1). 
Densitometry plots are shown on figure A1.  
CD10 expression in primary colorectal tumours 
Immunohistochemistry for expression of CD10 was performed on a TMA containing 84 primary 
colorectal cancers. Expression was seen both within the tumour epithelium and the stroma. 
Within the epithelium there was a mixture of membranous and cytoplasmic expression with 
varying levels of expression seen. The stromal cells generally showed weaker expression than 
the epithelium and mostly within the cytoplasm. Representative areas of high or low epithelial 
and stromal ratio of CD10 immunohistochemical staining are shown on Figure 5.  
Since both stromal and epithelial areas show staining for CD10, automated image analysis 
software was used to segment out and quantify the level of expression in each compartment. 
In addition, since cores were taken from 4 different regions (luminal area, mid-tumour, 
advancing edge and adjacent normal area), each region was examined individually. For an 
overall evaluation of expression, a total epithelial and stromal score was calculated from the 
sum of the ratios at the luminal, mid-tumour and advancing edge. To obtain a grade (low or 
high) of CD10 expression, the epithelial and stromal scores were split in two categories by the 
median value. 
Statistically significant associations were detected between high epithelial CD10 expression 
and presence of lymph node metastasis (P=0.001) and advanced Duke’s stage (P=0.001). A 
high stromal CD10 expression was also associated with KRAS wild-type status (P=0.043) 
(Table 2). 
Non-parametric Mann-Whitney ranks comparison of the four Duke’s stage groups analysed 
demonstrates statistically significant differences in epithelial CD10 expression are located 
between Duke’s stage A and C1 (P=0.012) and between stage B and C1 (P=0.029) (Figure 
6). 
 
 Epithelial CD10 score  Stromal CD10 score  
 Low High P-
value 
Low High P-value 
Grade 
1 
2 
3 
 
1 
33 
4 
 
1 
35 
1 
0.397  
1 
35 
1 
 
1 
32 
4 
0.380 
Tumour invasivenessa 
1 or 2 
3 or 4 
 
9 
29 
 
5 
32 
0.258  
5 
32 
 
9 
28 
0.235 
Duke’s stage 
A and B 
C1 and C2 
 
30 
16 
 
7 
21 
0.001  
24 
12 
 
24 
13 
0.871 
Ressection marginb 
Free 
Involved 
 
35 
1 
 
35 
2 
0.572  
33 
2 
 
35 
2 
0.954 
Vascular invasionb 
Present 
Absent 
 
15 
23 
 
22 
15 
0.083  
18 
19 
 
16 
21 
0.641 
LN metastasisb 
Present 
Absent 
 
17 
31 
 
20 
7 
0.001  
26 
11 
 
11 
13 
0.619 
KRAS statusb 
Wild-type 
Mutant 
 
21 
21 
 
13 
11 
0.745  
14 
16 
 
26 
10 
0.034 
Table 2 – Associations between clinicopathological variables and the epitehlial and stromal CD10 expression ratios. 
Pearson Chi-square was used to compare the CD10 high or low total epithelial and stromal scores for each of the 
categories considered. P-values <0.05 are considered statistically significant and are highlighted in bold.  
a - Tumour invasiveness categories grouping corresponds to: Submucosa invasion (1); Muscularis propria invasion 
(2); Muscularis and pericolorectal invasion (3); Visceral peritoneum and organs (4). 
 
Discussion   
In this study we have examined the role of tumour-associated CD10 in the CRC biology by 
comparing proliferation, migration and invasion of an isogenic pair of colorectal cancer cell 
lines derived from different tumour sites (i.e. SW480 was derived from the primary tumour 
whilst SW620 was derived from a metastatic deposit of the same tumour).  
CD10 knockdown was achieved by stable lentiviral transduction with PLKO.1-shCD10, 
confirmed by western blot (Figure 1). Following stable CD10 knockdown, a reduction in cell 
viability in SW620CD10- was observed albeit only after 72 hours in culture (Figure 2B). However, 
in SW480CD10-, there was no significant difference in cell viability (Figure 2A). Our results can 
be compared to those obtained by Mizerska-Kowalska et al, who have also observed a 
reduced proliferation (determined by the BrdU method) and increased proportion of apoptotic 
cells following CD10 knockdown in the CRC cell line LS180 (Mizerska-Kowalska et al. 2016). 
In their case however, cell cycle analysis showed G2/M arrest upon transient CD10 
knockdown in LS180 cells but not in SW620 (Mizerska-Kowalska et al. 2016). In contrast, 
although we have observed the same net effect on proliferation following CD10 knockdown, 
we have obtained a small but significant decrease in G2/M. These small shifts in proliferation 
could be due to a reduction of focal adhesion kinase phosphorylation at Tyr 397, regulated by 
CD10 intrinsic signalling (Mizerska-Kowalska et al. 2016). In terms of cell viability and 
proliferation, we must recognize the nature of the effects of the tumour microenvironment at 
the primary tumour (SW480) and metastatic site (SW620) and its long term implications in the 
metabolic activity of the cell lines hereby studied. 
Considering the proteolytic function of CD10 and previous associations with cancer 
progression and metastasis, we had expected that, in line with published studies (Fujimoto et 
al. 2005; Kuniyasu et al. 2010; Iwase et al. 2005; Jang et al. 2013; Fujita et al. 2010; Ohji et 
al. 2007), CD10 silencing would cause a reduction in migration and invasiveness of colorectal 
cancer cell lines. However our data showed that CD10 silencing resulted in increased 
migration and invasion of SW480CD10- cell lines, while in SW620CD10- there was no significant 
change (Figure 4). Comparable results were obtained by Mizerska-Kowalska et al. who 
showed that CD10 silencing caused an increase in invasion and migration in LS180. In 
SW620, they found that CD10 silencing caused increased  migration but reduced invasion 
(Mizerska-Kowalska et al. 2016). This also suggests that CD10 can inhibit cell migration and 
was attributed to the observation that CD10 silencing induced FAK phosphorylation thereby 
enhancing cell motility (Mizerska-Kowalska et al. 2016). The reason for the differences in the 
results in SW620 between our study and that of Mizerska-Kowalska is uncertain but, taking all 
the data together, there is evidence to suggest that, CD10 can inhibit cell migration.  
Knockdown of CD10 in SW480 caused a cadherin shift marked by a decrease in E-cadherin, 
coupled with an increase in N-cadherin expression (Figure 1). These results complement our 
observed differences for migration and invasion. Reduction of E-cadherin, often the result of 
EMT, is a frequent event during tumour progression and metastasis (Polyak & Weinberg 
2009). Reduced E-cadherin is often accompanied by an increase in N-cadherin during a 
‘cadherin switch’ which results in increased cell motility (Maeda et al. 2005). Unexpectedly, 
the cadherin switch occurred simultaneously with downregulation of Vimentin, Snail and Twist 
- markers characteristically associated with EMT. This downregulation would usually be 
associated with reduced motility. The data are suggestive of the plasticity of the mechanisms 
involved in processes of cell motility and EMT (Huang et al. 2013; Grigore et al. 2016). Loss 
of E-cadherin expression, with maintenance of high N-cadherin levels is likely to alter the 
adhesiveness of cells (Chu et al. 2006), and thus may explain the induction of motility without 
acquisition of a complete EMT shift in SW480CD10-. The precise mechanism by which CD10 
could be involved in regulating the EMT process by E-cadherin and N-cadherin deserves 
further investigation. 
Published data are inconsistent when IHC for CD10 is evaluated. Some studies have shown 
high CD10 expression in well and moderately-differentiated colon carcinomas relative to 
poorly differentiated ones (Sato et al. 1996; Fujimoto et al. 2005). Others have found a 
progressive increase in CD10 expression from normal to benign tumours to invasive disease 
(Jang et al. 2013; Yao et al. 2002). In our case only malignant colorectal adenocarcinomas 
were analysed, and therefore a stepwise association with CD10 expression in normal, benign 
and malignant tumours could not be made.  
While most studies on CD10 have used a positive/negative categorical or semi-quantitative 
evaluation, we have employed an automated IHC quantification method that excludes the 
observer-associated subjectivity. When expression of CD10 in the epithelial and stromal 
tumour compartments was analysed for its associations with clinicopathological variables, 
high CD10 expression in tumour epithelial cells was associate with advance disease (Dukes’ 
A & B versus Dukes’ C1 and C2, P=0.001). Differences in CD10 expression were particularly 
evident in a pairwise ranks comparison between Duke’s stage A and C1 (P=0.012) and B and 
C1 (P=0.029). Stromal CD10 expression was not associated to Duke’s stage. Similarly, 
epithelial CD10 expression was associated with presence of lymph node metastasis 
(P<0.001). While this is not completely in agreement with our in vitro results showing CD10 as 
an inhibitor of migration and invasion in SW480, in vivo epithelial CD10 expression could be 
counteracting anti-tumoural effect of peptides such as met-enkephalin, and as a consequence, 
promoting invasion and lymph node metastasis (Kuniyasu et al. 2010). It has also been shown 
that CD10 enzymatic activity degrades migration-inducing peptides such as bombesin and 
endothelin (Terauchi et al. 2005; Zheng et al. 2006; Wang et al. 2017). It is therefore feasible 
that CD10 activitiy in vivo is conditioned by the relative abundance of such peptides in different 
tumour compartments and tumour stages, explaining discrepancies to data obtained in vitro 
where extrinsic peptidase activity of CD10 could not be assessed. 
Conclusion 
Considering the results hereby presented, it is possible that proteolytic effects of CD10-
expression are controlled by the surrounding microenvironment and its significance depends 
on the tumour stage and interaction of stroma and epithelium. Our findings suggest that CD10 
knockdown has the potential to increase the migrating and invading ability of the primary 
colorectal cancer cell line SW480, but not that of the matched metastasis SW620. Intriguingly, 
results of our TMA analysis on CD10 immunostaining show and association with advanced 
Duke’s stage and presence of lymph node metastasis. 
In vitro studies which do not fully recapitulate the rich microenvironment displayed within 
colorectal tumour could nevertheless suggest alterations in proliferation, migration and 
invasion together with shifts in EMT markers caused by CD10 knockdown, all of which seem 
to be influenced by the stage of tumour development. Due to the importance of understanding 
mechanisms underlying tumour invasion and metastasis, further research is warranted to 
clarify the role of CD10 in EMT and tumour progression. 
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Appendix: Supplementary tables 
 
Primary antibody Diluent  Dilution Secondary 
antibody 
Dilution 
CD10 Rabbit -Human  
(Abcam, 
EPR5904-110 
ab208778) 
5% 
skimmed 
milk, 
TBST 
 1:500 
 
Goat -Rabbit  
(Sigma Aldrich 
A6154)… 
1:1000 
N-Cadherin Rabbit -Human  
(Abcam, ab12221) 
5% 
skimmed 
milk, 
TBST 
 1:1000 Goat -Rabbit 
(Sigma Aldrich 
A6154) 
1:1000 
E-Cadherin Rabbit -Human  
(CST, #3195) 
5% BSA, 
TBST 
 1:1000 Goat -Rabbit  
(Sigma Aldrich 
A6154) 
1:1000 
Snail Rabbit -Human  
(CST, #3879S) 
5% BSA, 
TBST 
 1:1000 Goat -Rabbit  
(Sigma Aldrich 
A6154) 
1:1000 
Vimentin Rabbit -Human  
(CST, #5741S) 
5% BSA, 
TBST 
 1:1000 Goat -Rabbit  
(Sigma Aldrich 
A6154) 
1:1000 
Twist Mouse -Human  
(Abcam, 
ab175430) 
5% BSA, 
TBST 
 1:1000 Rabbit -Mouse  
(Sigma Aldrich, 
A4416) 
1:1000 
-Tubulin Mouse -Human  
(Abcam, DM1A 
ab7291) 
5% 
skimmed 
milk, 
TBST 
 1:2000 Rabbit -Mouse  
(Sigma Aldrich, 
A4416) 
1:5000 
Table A1-Dilution ratios for primary and secondary antibodies and diluent used for 
each antibody. 
  
  Frequency(N) (%) 
Resection type (N=81)   
Anterior resection  23 27.4 
Aper 2 2.4 
Caecum resection 1 1.2 
Hartmanns  1 1.2 
Left hemicolectomy  1 1.2 
Rectum resection 1 1.2 
Right hemicoloctomy 33 39.3 
Sigmoid colectomy 16 19.0 
Small intestine resection  1 1.2 
Total colectomy 1 1.2 
Transverse colon resection 1 1.2 
Tumour grade (N=84)   
1 2 2.4 
2 77 91.7 
3 5 6.0 
Invasiveness (N=84)   
Submucosa invasion (1) 3 3.6 
Muscularis propria invasion 
(2) 
12 14.3 
Muscularis and pericolorectal 
invasion (3) 
46 54.8 
Visceral peritoneum and 
organs (4) 
23 27.4 
Resection margin (N=82) 
Free 
Involved 
 
78 
4 
 
95.1 
4.9 
Vascular invasion (N=84)   
Absent  42 50.0 
Present 42 50.0 
Duke’s stage (N=83)   
A 13 15.5 
B 38 45.2 
C1 28 33.3 
C2 4 4.8 
KRAS mutation status 
(N=75) 
  
Wild-type  46 54.8 
Mutant 29 34.5 
LN Metastasis (N=84)   
Absent 53 63.1 
Present 31 36.9 
Table B1- Summary of clinicopathological characteristics in the patient samples 
included in this study. 
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